Heterologous Expression and CRISPR/Cas9-Assisted Manipulation of the Hybrid Gene Cluster Specifying the Biosynthesis of Meroterpenoids and Phenazines
ACS Synthetic Biology · 2026
DOI: 10.1021/acssynbio.5c00531 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Synthetic Biology, 2026. Verfasst von Olha Schneider und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Division of Pharmacognosy, University of Vienna, Vienna 1090, Austria. Hauptthemen laut MEDLINE: Terpenes. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund, Universität Wien.
Abstract (Originalsprache)
High Resolution Image Download MS PowerPoint Slide A hybrid gene cluster, mfq, predicted to govern the biosynthesis of both meroterpenoids and phenaziterpenes, was cloned from the genome of Streptomyces sp. S4.7 and introduced into the heterologous host Streptomyces coelicolor M1154. The biosynthesis of the meroterpenoids marfuraquinocins C and D, previously isolated from Streptomyces niveus SCSIO 3406, as well as a new congener, marfuraquinocin E, which exhibited antibacterial activity, was activated upon overexpression of the regulatory protein MfqF. However, production of neither phenaziterpenes nor phenazines was detected. The structure of marfuraquinocin E was elucidated, revealing the attachment of a terpene moiety at C-2, in contrast to C-6 as seen in the known congeners A–D. Using the CRISPR/Cas9 system, several genes in the mfq cluster were inactivated, confirming the role of MfqW as a prenyltransferase specific to the meroterpenoid pathway. Both gene overexpression and further knockouts provided the first insights into the complex regulation of this hybrid gene cluster. To restore the presumably deficient phenazine biosynthetic pathway, a gene encoding a PhzF homologue from another gene cluster in S4.7 was heterologously expressed alongside the mfq cluster, leading to the production of 1,6-phenazine dicarboxylic acid upon MfqF overexpression. This work lays the foundation for elucidating the complete biosynthetic pathway of marfuraquinocins and its potential coregulation with that of phenazines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Division of Pharmacognosy, University of Vienna, Vienna 1090, Austria.
- Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna 1090, Austria.
- Department of Chemistry, University of Turin, Via P. Giuria 7, Turin 10125, Italy.
- Department of Chemistry, University of Rome "La Sapienza", P.le A. Moro, 5, Rome 00185, Italy.
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States.
ORCID-Profile: Martin Zehl, Jan-Fang Cheng, Verena M Dirsch, Sergey B Zotchev
Förderung
- Austrian Science Fund
- Universität Wien
Zitieren
APA
Schneider, O., Zehl, M., Miele, M., Pace, V., Brungs, C., Cheng, J. F., Hummelbrunner, S., Dirsch, V. M., & Zotchev, S. B. (2026). Heterologous Expression and CRISPR/Cas9-Assisted Manipulation of the Hybrid Gene Cluster Specifying the Biosynthesis of Meroterpenoids and Phenazines. ACS Synthetic Biology. https://doi.org/10.1021/acssynbio.5c00531
Vancouver
Schneider O, Zehl M, Miele M, Pace V, Brungs C, Cheng JF, et al. Heterologous Expression and CRISPR/Cas9-Assisted Manipulation of the Hybrid Gene Cluster Specifying the Biosynthesis of Meroterpenoids and Phenazines. ACS Synthetic Biology. 2026. doi:10.1021/acssynbio.5c00531
BibTeX
@article{Schneider2026,
author = {Schneider, Olha and Zehl, Martin and Miele, Margherita and Pace, Vittorio and Brungs, Corinna and Cheng, Jan-Fang and Hummelbrunner, Scarlet and Dirsch, Verena M and Zotchev, Sergey B},
title = {Heterologous Expression and CRISPR/Cas9-Assisted Manipulation of the Hybrid Gene Cluster Specifying the Biosynthesis of Meroterpenoids and Phenazines},
journal = {ACS Synthetic Biology},
year = {2026},
doi = {10.1021/acssynbio.5c00531}
}
EUVIMED